Rat brain tumor models in experimental neuro-oncology: The C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas

Journal of Neuro-Oncology

Volumn 94, Issue 3, 2009, Pages 299-312

  Barth, Rolf F ^a   Kaur, Balveen ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

9L; BT4C; C6; CNS 1; F98; Rat brain tumor models; RG2; RT 2; T9

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CARMUSTINE; ETHYLNITROSOUREA; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; METHYLNITROSOUREA; PLATELET DERIVED GROWTH FACTOR; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; AVIAN SARCOMA VIRUS; BERLIN DRUCKSEY IX RAT; BRAIN STEM TUMOR; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; DRUG RESEARCH; DRUG SCREENING; FISCHER 344 RAT; GENE OVEREXPRESSION; GLIOMA; GLIOSARCOMA; HUMAN; IMMUNOGENICITY; LEWIS RAT; NEUTRON CAPTURE THERAPY; NONHUMAN; RAT STRAIN; REVIEW; WISTAR RAT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; MICE; RATS;

EID: 69249226362     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9875-7     Document Type: Review

References (149)

1. Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12:5288-5297. doi: 10.1158/1078-0432.CCR-06-0438
2. Lampson LA (2001) New animal models to probe brain tumor biology, therapy, and immunotherapy: Advantages and remaining concerns. J Neurooncol 53:275-287. doi: 10.1023/A:1012230113527
3. Kimmelman J, Nalbantoglu J (2007) Faithful companions: A proposal for neurooncology trials in pet dogs. Cancer Res 67:4541-4544. doi: 10.1158/ 0008-5472.CAN-06-3792
4. Krushelnycky BW, Farr-Jones MA, Mielke B et al (1991) Development of a large-animal human brain tumor xenograft model in immunosuppressed cats. Cancer Res 51:2430-2437
5. Barth RF (1998) Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36:91-102. doi: 10.1023/A:1005805203044
6. Candolfi M, Curtin JF, Nichols WS et al (2007) Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression. J Neurooncol 85:133-148. doi: 10.1007/ s11060-007-9400-9
7. Reilly KM, Rubin JB, Gilbertson RJ et al (2008) Rethinking brain tumors: the fourth mouse models of human cancers consortium nervous system tumors workshop. Cancer Res 68:5508-5511. doi: 10.1158/ 0008-5472.CAN-08-0703
8. Barker M, Hoshino T, Gurcay O et al (1973) Development of an animal brain tumor model and its response to therapy with 1, 3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 33:976-986
9. Kobayashi N, Allen N, Clendenon NR et al (1980) An improved rat brain-tumor model. J Neurosurg 53:808-815
10. Landen JW, Hau V, Wang M et al (2004) Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 10:5187-5201. doi: 10.1158/1078-0432.CCR-04-0360
11. Lal S, Lacroix M, Tofilon P et al (2000) An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 92:326-333
12. Saini M, Roser F, Samii M et al (2004) A model for intratumoural chemotherapy in the rat brain. Acta Neurochir (Wien) 146:731-734. doi: 10.1007/s00701-004-0261-0
13. Benda P, Lightbody J, Sato G et al (1968) Differentiated rat glial cell strain in tissue culture. Science 161:370-371. doi: 10.1126/ science.161.3839.370
14. Schmidek HH, Nielsen SL, Schiller AL et al (1971) Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg 34:335-340
15. Pfeiffer SE, Herschman HR, Lightbody J et al (1970) Synthesis by a clonal line of rat glial cells of a protein unique to the nervous system. J Cell Physiol 75:329-339. doi: 10.1002/jcp.1040750309
16. Schlegel J, Piontek G, Kersting M et al (1999) The p16/Cdkn2a/Ink4a gene is frequently deleted in nitrosourea-induced rat glial tumors. Pathobiology 67:202-206. doi: 10.1159/000028073
17. Asai A, Miyagi Y, Sugiyama A et al (1994) Negative effects of wild-type p53 and s-myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 19:259-268. doi: 10.1007/BF01053280
18. Sibenaller ZA, Etame AB, Ali MM et al (2005) Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg Focus 19:E1. doi: 10.3171/foc.2005.19.4.2
19. Guo P, Hu B, Gu W et al (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162:1083-1093
20. Heimberger AB, Suki D, Yang D et al (2005) The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3:38. doi: 10.1186/ 1479-5876-3-38
21. Morford LA, Boghaert ER, Brooks WH et al (1997) Insulin-like growth factors (IGF) enhance three-dimensional (3D) growth of human glioblastomas. Cancer Lett 115:81-90. doi: 10.1016/S0304-3835(97)04717-4
22. Assanah M, Lochhead R, Ogden A et al (2006) Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 26:6781-6790. doi: 10.1523/JNEUROSCI.0514-06.2006
23. Nakada M, Niska JA, Tran NL et al (2005) EphB2/R-ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 167:565-576
24. Lampson LA, Lampson MA, Dunne AD (1993) Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: Use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ. Cancer Res 53:176-182
25. Doblas S, Saunders D, Kshirsagar P et al (2008) Phenyl-tert-butylnitrone induces tumor regression and decreases angiogenesis in a C6 rat glioma model. Free Radic Biol Med 44:63-72. doi: 10.1016/ j.freeradbiomed.2007.09.006
26. Solly F, Fish R, Simard B et al (2008) Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model. Cancer Gene Ther 15:685-692. doi: 10.1038/cgt.2008.36
27. Ahmed AE, Jacob S, Nagy AA et al (2008) Dibromoacetonitrile-induced protein oxidation and inhibition of proteasomal activity in rat glioma cells. Toxicol Lett 179:29-33. doi: 10.1016/j.toxlet.2008.03.017
28. Zhao S, Zhang X, Zhang J et al (2008) Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains. J Chemother 20:253-262
29. Sheehan J, Ionescu A, Pouratian N et al (2008) Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation: laboratory investigation. J Neurosurg 108:972-978. doi: 10.3171/JNS/2008/ 108/5/0972
30. Mannino S, Molinari A, Sabatino G et al (2008) Intratumoral vs systemic administration of meta-tetrahydroxyphenylchlorin for photodynamic therapy of malignant gliomas: Assessment of uptake and spatial distribution in C6 rat glioma model. Int J Immunopathol Pharmacol 21:227-231
31. Yang WQ, Lun X, Palmer CA et al (2004) Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: Racine and nonhuman primates. Clin Cancer Res 10:8561-8576. doi: 10.1158/ 1078-0432.CCR-04-0940
32. Tanriover N, Ulu MO, Sanus GZ et al (2008) The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model. Neurol Res 30:511-517. doi: 10.1179/174313208X289516
33. Parsa AT, Chakrabarti I, Hurley PT et al (2000) Limitations of the C6/ Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy. Neurosurgery 47:993-999. doi: 10.1097/ 00006123-200010000-00050 discussion 999-1000
34. Trojan J, Johnson TR, Rudin SD et al (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259:94-97. doi: 10.1126/ science.8418502
35. Johnson TR, Trojan J, Rudin SD, Ilan J, Tykocinski ML (1993) Evoking an immune response to glioblastoma cells transfected with episome-based plasmid expressing insulin-like growth factor I. In: Levine AJ, Schmidek HH (eds) Molecular genetics of nervous system tumors. Wiley-Liss Inc., New York, pp 387-400
36. Karmakar S, Olive MF, Banik NL et al (2007) Intracranial stereotaxic cannulation for development of orthotopic glioblastoma allograft in Sprague-Dawley rats and histoimmunopathological characterization of the brain tumor. Neurochem Res 32:2235-2242. doi: 10.1007/s11064-007-9450-6
37. Assadian S, Aliaga A, Del Maestro RF et al (2008) FDG-PET imaging for the evaluation of antiglioma agents in a rat model. Neuro-oncol 10:292-299. doi: 10.1215/15228517-2008-014
38. Valable S, Lemasson B, Farion R et al (2008) Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: A longitudinal in vivo and ex vivo study. NMR Biomed 21:1043-1056. doi: 10.1002/nbm.1278
39. Valable S, Barbier EL, Bernaudin M et al (2008) In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. Neuroimage 40:973-983. doi: 10.1016/j.neuroimage.2008.01.005
40. Shen G, Shen F, Shi Z et al (2008) Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim 44:280-289. doi: 10.1007/s11626-008-9115-z
41. Benda P, Someda K, Messer J et al (1971) Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 34:310-323
42. Ghods AJ, Irvin D, Liu G et al (2007) Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645-1653. doi: 10.1634/ stemcells.2006-0624
43. Barcellos-Hoff MH, Linfoot PA, Marton LJ et al (1992) Production of stable phenotypes from 9L rat brain tumor multicellular spheroids treated with 1, 3-bis(2-chloroethyl)-1-nitrosourea. Int J Cancer 52:409-413. doi: 10.1002/ijc.2910520314
44. Schepkin VD, Lee KC, Kuszpit K et al (2006) Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed 19:1035-1042. doi: 10.1002/nbm.1074
45. Black KL, Yin D, Konda BM et al (2008) Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models. Brain Res 1227:198-206. doi: 10.1016/j.brainres.2008.06.046
46. Fross RD, Warnke PC, Groothuis DR (1991) Blood flow and blood-to-tissue transport in 9L gliosarcomas: The role of the brain tumor model in drug delivery research. J Neurooncol 11:185-197. doi: 10.1007/BF00165526
47. Khan A, Jallo GI, Liu YJ et al (2005) Infusion rates and drug distribution in brain tumor models in rats. J Neurosurg 102:53-58
48. Warnke PC, Blasberg RG, Groothuis DR (1987) The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann Neurol 22:300-305. doi: 10.1002/ana.410220304
49. Bansal A, Shuyan W, Hara T et al (2008) Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing Fisher rats. Eur J Nucl Med Mol Imaging 35:1192-1203. doi: 10.1007/ s00259-008-0736-y
50. Yuan H, Schroeder T, Bowsher JE et al (2006) Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 47:989-998
51. Wolff JE, Molenkamp G, Hotfilder M et al (1997) Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Klin Padiatr 209:275-277. doi: 10.1055/ s-2008-1043962
52. Yang H, Chopp M, Zhang X et al (2007) Using behavioral measurement to assess tumor progression and functional outcome after antiangiogenic treatment in mouse glioma models. Behav Brain Res 182:42-50. doi: 10.1016/j.bbr.2007.05.013
53. Regnard P, Le Duc G, Brauer-Krisch E et al (2008) Irradiation of intracerebral 9L gliosarcoma by a single array of microplanar x-ray beams from a synchrotron: Balance between curing and sparing. Phys Med Biol 53:861-878. doi: 10.1088/0031-9155/53/4/003
54. Bencokova Z, Pauron L, Devic C et al (2008) Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin. J Neurooncol 86:13-21. doi: 10.1007/s11060-007-9433-0
55. Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728-2737. doi: 10.1158/1078-0432.CCR-06-3039
56. Barba D, Hardin J, Ray J et al (1993) Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 79:729-735
57. Iwadate Y, Inoue M, Saegusa T et al (2005) Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 11:3821-3827. doi: 10.1158/1078-0432.CCR-04-1485
58. Kumar S, Brown SL, Kolozsvary A et al (2008) Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells. J Neurooncol 90:19-24. doi: 10.1007/s11060-008-9635-0
59. Miletic H, Fischer Y, Litwak S et al (2007) Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 15:1373-1381. doi: 10.1038/ sj.mt.6300155
60. Chignola R, Foroni R, Franceschi A et al (1995) Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin. Br J Cancer 72:607-614
61. Liu Y, Wang Q, Kleinschmidt-DeMasters BK et al (2007) TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J Neurooncol 81:149-162. doi: 10.1007/s11060-006-9222-1
62. Aghi M, Chou TC, Suling K et al (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 59:3861-3865
63. Madara J, Krewet JA, Shah M (2005) Heat shock protein 72 expression allows permissive replication of oncolytic adenovirus dl1520 (ONYX-015) in rat glioblastoma cells. Mol Cancer 4:12. doi: 10.1186/1476-4598-4-12
64. Blume MR, Wilson CP, Vasquez DA (1974) Immune response to a transplantable intracerebral glioma in rats. In: Sane K, Ishi S, Le Vey D (eds) Recent progress in neurological surgery. Excerpta Medica, Amsterdam, pp 129-134
65. Denlinger RH, Axler DA, Koestner A et al (1975) Tumor-specific transplantation immunity to intracerebral challenge with cells from a methylnitrosourea-induced brain tumor. J Med 6:249-259
66. Morantz RA, Wood GW, Foster M et al (1979) Macrophages in experimental and human brain tumors. Part 1: Studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J Neurosurg 50:298-304
67. Chen CY, Chang YN, Ryan P et al (1995) Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". Hum Gene Ther 6:1467-1476. doi: 10.1089/hum.1995.6.11-1467
68. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 46:5276-5281
69. Coderre J, Rubin P, Freedman A et al (1994) Selective ablation of rat brain tumors by boron neutron capture therapy. Int J Radiat Oncol Biol Phys 28:1067-1077
70. Moriuchi S, Wolfe D, Tamura M et al (2002) Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 9:584-591. doi: 10.1038/sj.gt.3301693
71. Namba H, Tagawa M, Miyagawa T et al (2000) Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir. Cancer Gene Ther 7:947-953. doi: 10.1038/sj.cgt.7700172
72. Smilowitz HM, Micca PL, Nawrocky MM et al (2000) The combination of boron neutron-capture therapy and immunoprophylaxis for advanced intracerebral gliosarcomas in rats. J Neurooncol 46:231-240. doi: 10.1023/A:1006409721365
73. Stojiljkovic M, Piperski V, Dacevic M et al (2003) Characterization of 9L glioma model of the Wistar rat. J Neurooncol 63:1-7. doi: 10.1023/ A:1023732619651
74. Bhattacharya P, Chekmenev EY, Perman WH et al (2007) Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson 186:150-155. doi: 10.1016/j.jmr.2007.01.017
75. Jallo GI, Volkov A, Wong C et al (2006) A novel brainstem tumor model: functional and histopathological characterization. Childs Nerv Syst 22:1519-1525. doi: 10.1007/s00381-006-0174-8
76. Saito R, Bringas J, Mirek H et al (2004) Invasive phenotype observed in 1, 3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: A tumor model mimicking a recurrent malignant glioma. J Neurosurg 101:826-831
77. Schepkin VD, Lee KC, Kuszpit K et al (2006) Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed 19:1035-1042. doi: 10.1002/nbm.1074
78. Kida Y, Cravioto H, Hochwald GM et al (1983) Immunity to transplantable nitrosourea-induced neurogenic tumors. II. Immunoprophylaxis of tumors of the brain. J Neuropathol Exp Neurol 42:122-135. doi: 10.1097/ 00005072-198303000-00002
79. Jeffes EW, Zhang JG, Hoa N et al (2005) Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma. J Immunol 174:2533-2543
80. Pietronigro D, Drnovsky F, Cravioto H et al (2003) DTI-015 produces cures in T9 gliosarcoma. Neoplasia 5:17-22
81. Shibuya N, Hochgeschwender U, Kida Y et al (1984) Immunity to transplantable nitrosourea-induced neurogenic tumors. III. Systemic adoptive transfer of immunity. J Neuropathol Exp Neurol 43:426-438. doi: 10.1097/00005072-198407000-00007
82. Harada K, Yoshida J, Mizuno M et al (1995) Growth inhibition of intracerebral rat glioma by transfection-induced human interferon-beta. J Surg Oncol 59:105-109
83. Ko L, Koestner A, Wechsler W (1980) Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol 51:23-31. doi: 10.1007/BF00688846
84. Weizsacker M, Nagamune A, Winkelstroter R et al (1982) Radiation and drug response of the rat glioma RG2. Eur J Cancer Clin Oncol 18:891-895. doi: 10.1016/0277-5379(82)90200-0
85. Ferrier MC, Sarin H, Fung SH et al (2007) Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 9:546-555. doi: 10.1593/neo.07289
86. Ningaraj NS, Rao M, Hashizume K et al (2002) Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther 301:838-851. doi: 10.1124/jpet.301.3.838
87. Hashizume K, Black KL (2002) Increased endothelial vesicular transport correlates with increased blood-tumor barrier permeability induced by bradykinin and leukotriene C4. J Neuropathol Exp Neurol 61:725-735
88. Zagorac D, Jakovcevic D, Gebremedhin D et al (2008) Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. J Cereb Blood Flow Metab 28:1431-1439. doi: 10.1038/ jcbfm.2008.31
89. Wang W, Tai CK, Kershaw AD et al (2006) Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 20:E25. doi: 10.3171/foc.2006.20.1.8
90. Miknyoczki S, Chang H, Grobelny J et al (2007) The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6:2290-2302. doi: 10.1158/1535-7163.MCT-07-0062
91. Tsai NM, Lin SZ, Lee CC et al (2005) The antitumor effects of angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 11:3475-3484. doi: 10.1158/1078-0432.CCR-04-1827
92. Shen DH, Marsee DK, Schaap J et al (2004) Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 11:161-169. doi: 10.1038/sj.gt.3302147
93. Oshiro S, Liu Y, Fukushima T et al (2001) Modified immunoregulation associated with interferon-gamma treatment of rat glioma. Neurol Res 23:359-366. doi: 10.1179/016164101101198569
94. Kurozumi K, Hardcastle J, Thakur R et al (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99:1768-1781. doi: 10.1093/jnci/djm229
95. Wakimoto H, Fulci G, Tyminski E et al (2004) Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 11:214-223. doi: 10.1038/sj.gt.3302143
96. Mathieu D, Lecomte R, Tsanaclis AM et al (2007) Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. Can J Neurol Sci 34:296-306
97. von Eckardstein KL, Patt S, Kratzel C et al (2005) Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neurooncol 72:209-215. doi: 10.1007/ s11060-004-3010-6
98. Biston MC, Joubert A, Adam JF et al (2004) Cure of Fischer rats bearing radioresistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays. Cancer Res 64:2317-2323. doi: 10.1158/ 0008-5472.CAN-03-3600
99. Rousseau J, Boudou C, Barth RF et al (2007) Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation. Clin Cancer Res 13:5195-5201. doi: 10.1158/1078-0432.CCR-07-1002
100. Rousseau R, Barth RF, Moeschberger ML et al. (2008) Efficacy of intracerebral delivery of carboplatin in combination with photon irradiation for treatment of F98 glioma bearing rats. Int J Radiat Oncol Biol Phys 73:530-536
101. Barth RF, Yang W, Coderre JA (2003) Rat brain tumor models to assess the efficacy of boron neutron capture therapy: A critical evaluation. J Neurooncol 62:61-74
102. Yang W, Wu G, Barth RF et al (2008) Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 14:883-891. doi: 10.1158/ 1078-0432.CCR-07-1968
103. Cho JY, Shen DH, Yang W et al (2002) In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 9:1139-1145. doi: 10.1038/ sj.gt.3301787
104. Adam JF, Joubert A, Biston MC et al (2006) Prolonged survival of Fischer rats bearing F98 glioma after iodine-enhanced synchrotron stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 64:603-611. doi: 10.1016/ j.ijrobp.2005.09.004
105. Blanchard J, Mathieu D, Patenaude Y et al (2006) MR-pathological comparison in F98-Fischer glioma model using a human gantry. Can J Neurol Sci 33:86-91
106. Zhang J, van Zijl PC, Laterra J et al (2007) Unique patterns of diffusion directionality in rat brain tumors revealed by high-resolution diffusion tensor MRI. Magn Reson Med 58:454-462. doi: 10.1002/mrm.21371
107. Zhang D, Feng XY, Henning TD et al. (2008) MR imaging of tumor angiogenesis using sterically stabilized gd-DTPA liposomes targeted to CD105. Eur J Radiol. doi: 10.1016/j.ejrad.2008.04.022
108. Wu X, Hu J, Zhou L et al (2008) In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory investigation. J Neurosurg 108:320-329. doi: 10.3171/JNS/2008/108/2/0320
109. Tzeng JJ, Barth RF, Orosz CG et al (1991) Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 51:2373-2378
110. Paul DB, Barth RF, Yang W et al (2000) B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity. Gene Ther 7:993-999. doi: 10.1038/sj.gt.3301209
111. Clavreul A, Delhaye M, Jadaud E et al (2006) Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model. J Neurooncol 79:9-17. doi: 10.1007/ s11060-005-9115-8
112. Hanissian SH, Teng B, Akbar U et al (2005) Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma. Brain Res 1047:56-64. doi: 10.1016/j.brainres.2005.04.017
113. von Eckardstein KL, Patt S, Zhu J et al (2001) Short-term neuropathological aspects of in vivo suicide gene transfer to the F98 rat glioblastoma using liposomal and viral vectors. Histol Histopathol 16:735-744
114. Fenstermaker RA, Capala J, Barth RF et al (1995) The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells. Leukemia 9(Suppl 1):S106-S112
115. Yang W, Barth RF, Wu G et al (2005) Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res 11:341-350
116. Wu G, Yang W, Barth RF et al (2007) Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res 13:1260-1268. doi: 10.1158/ 1078-0432.CCR-06-2399
117. Wu G, Barth RF, Yang W et al (2006) Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 5:52-59. doi: 10.1158/1535-7163.MCT-05-0325
118. Bryant MJ, Chuah TL, Luff J et al (2008) A novel rat model for glioblastoma multiforme using a bioluminescent F98 cell line. J Clin Neurosci 15:545-551. doi: 10.1016/j.jocn.2007.04.022
119. Ernestus RI, Wilmes LJ, Hoehn-Berlage M (1992) Identification of intracranial liqor metastases of experimental stereotactically implanted brain tumors by the tumor-selective MRI contrast agent MnTPPS. Clin Exp Metastasis 10:345-350. doi: 10.1007/BF00058174
120. Kruse CA, Molleston MC, Parks EP et al (1994) A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: A comparison to 9L gliosarcoma. J Neurooncol 22:191-200. doi: 10.1007/ BF01052919
121. Kielian T, van Rooijen N, Hickey WF (2002) MCP-1 expression in CNS-1 astrocytoma cells: Implications for macrophage infiltration into tumors in vivo. J Neurooncol 56:1-12. doi: 10.1023/A:1014495613455
122. Platten M, Kretz A, Naumann U et al (2003) Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54:388-392. doi: 10.1002/ana.10679
123. Owens GC, Orr EA, DeMasters BK et al (1998) Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res 58:2020-2028
124. Lapointe M, Lanthier J, Moumdjian R et al (2005) Expression and activity of l-isoaspartyl methyltransferase decrease in stage progression of human astrocytic tumors. Brain Res Mol Brain Res 135:93-103. doi: 10.1016/j.molbrainres.2004.12.008
125. Matthews RT, Gary SC, Zerillo C et al (2000) Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem 275:22695-22703. doi: 10.1074/jbc.M909764199
126. Nutt CL, Zerillo CA, Kelly GM et al (2001) Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in lewis rats. Cancer Res 61:7056-7059
127. Biglari A, Bataille D, Naumann U et al (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11:721-732. doi: 10.1038/sj.cgt.7700783
128. Ali S, Curtin JF, Zirger JM et al (2004) Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): Treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 10:1071-1084. doi: 10.1016/ j.ymthe.2004.08.025
129. Laerum OD, Rajewsky MF (1975) Neoplastic transformation of fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo. J Natl Cancer Inst 55:1177-1187
130. Laerum OD, Rajewsky MF, Schachner M et al (1977) Phenotypic properties of neoplastic cell lines developed from fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 89:273-295. doi: 10.1007/BF00283783
131. Stuhr LE, Raa A, Oyan AM et al (2007) Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. J Neurooncol 85:191-202. doi: 10.1007/ s11060-007-9407-2
132. Pulkkinen M, Pikkarainen J, Wirth T et al (2008) Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. Eur J Pharm Biopharm 70:66-74. doi: 10.1016/ j.ejpb.2008.04.018
133. Raty JK, Airenne KJ, Marttila AT et al (2004) Enhanced gene delivery by avidin-displaying baculovirus. Mol Ther 9:282-291. doi: 10.1016/ j.ymthe.2003.11.004
134. Huszthy PC, Brekken C, Pedersen TB et al (2006) Antitumor efficacy improved by local delivery of species-specific endostatin. J Neurosurg 104:118-128. doi: 10.3171/jns.2006.104.1.118
135. Sandstrom M, Johansson M, Bergstrom P et al (2008) Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 88:1-9. doi: 10.1007/ s11060-008-9527-3
136. Vallbo C, Bergenheim T, Hedman H et al (2002) The antimicrotubule drug estramustine but not irradiation induces apoptosis in malignant glioma involving AKT and caspase pathways. J Neurooncol 56:143-148. doi: 10.1023/A:1014562503097
137. Yoshida D, Noha M, Watanabe K et al (2001) The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study. J Neurooncol 52:37-47. doi: 10.1023/A:1010653613588
138. Andersson U, Grankvist K, Bergenheim AT et al (2002) Rapid induction of long-lasting drug efflux activity in brain vascular endothelial cells but not malignant glioma following irradiation. Med Oncol 19:1-9. doi: 10.1385/MO:19:1:1
139. Griffin JL, Lehtimaki KK, Valonen PK et al (2003) Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res 63:3195-3201
140. Garcia-Cabrera I, Edvardsen K, Tysnes BB et al (1996) The lac-z reporter gene: A tool for in vitro studies of malignant glioma cell invasion. Invasion Metastasis 16:107-115
141. Pedersen PH, Edvardsen K, Garcia-Cabrera I et al (1995) Migratory patterns of lac-z transfected human glioma cells in the rat brain. Int J Cancer 62:767-771. doi: 10.1002/ijc.2910620620
142. Copeland DD, Talley FA, Bigner DD (1976) The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats. Am J Pathol 83:149-176
143. Prabhu SS, Broaddus WC, Oveissi C et al (2000) Determination of intracranial tumor volumes in a rodent brain using magnetic resonance imaging, Evans blue, and histology: A comparative study. IEEE Trans Biomed Eng 47:259-265. doi: 10.1109/10.821776
144. Beckman WC Jr, Powers SK, Brown JT et al (1987) Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo. Cancer 59:266-270. doi: 10.1002/ 1097-0142(19870115)59:2<266::AID-CNCR2820590215>3.0.CO;2-6
145. Valerie K, Hawkins W, Farnsworth J et al (2001) Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther 8:3-8. doi: 10.1038/sj.cgt.7700265
146. Valerie K, Brust D, Farnsworth J et al (2000) Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther 7:879-884. doi: 10.1038/sj.cgt.7700185
147. Shah MR, Ramsey WJ (2003) CD8 + T-cell mediated anti-tumor responses cross-reacting against 9L and RT2 rat glioma cell lines. Cell Immunol 225:113-121. doi: 10.1016/j.cellimm.2003.10.004
148. Mourad PD, Farrell L, Stamps LD et al (2003) Quantitative assessment of glioblastoma invasion in vivo. Cancer Lett 192:97-107. doi: 10.1016/ S0304-3835(02)00637-7
149. Beutler AS, Banck MS, Wedekind D et al (1999) Tumor gene therapy made easy: Allogeneic major histocompatibility complex in the C6 rat glioma model. Hum Gene Ther 10:95-101